



## Melatonin and Cancer: Current Challenges and Future Perspectives

Guest Editors:

### **Dr. Francisco López-Muñoz**

Faculty of Health Sciences,  
University Camilo José Cela,  
C/castillo de Alarcón, 49, Urb.  
Villafranca del Castillo, 28692  
Madrid, Spain

### **Prof. Dr. Alejandro Romero Martínez**

Department of Pharmacology  
and Toxicology, Faculty of  
Veterinary Medicine,  
Complutense University of  
Madrid, Avda. Puerta de Hierro  
s/n, 28040 Madrid, Spain

Deadline for manuscript  
submissions:

**closed (5 August 2024)**

### **Message from the Guest Editors**

Melatonin has increasingly emerged in oncology as a naturally occurring bioactive molecule with anticancer properties and a pharmacological safety profile optimal for joining the currently available pharmacopeia. The anti-angiogenic and anti-metastatic effects of melatonin suggest that it may have potential therapeutic applications in the treatment of cancer. In addition, melatonin has been shown to inhibit the migration and invasion of cancer cells, which are important steps in the process of tumor metastasis. This effect is believed to be mediated by the downregulation of matrix metalloproteinases (MMPs). We focused our attention on the molecular mechanisms underlying the multiple oncostatic actions displayed by melatonin and its potential as an adjuvant in preclinical models, in the treatment of cancer patients, and in novel-combination chemotherapeutic cocktails. This Special Issue aims to serve as a forum to bring together researchers of different fields to advance the knowledge on the therapeutic use of melatonin against cancer.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)